<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00889642</url>
  </required_header>
  <id_info>
    <org_study_id>Dharma-NSCO3</org_study_id>
    <nct_id>NCT00889642</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of an Iontophoretic Patch Containing Lidocaine and Epinephrine for Venipuncture in Healthy Adult Volunteers</brief_title>
  <official_title>A Multicenter Double-Blind Randomized Placebo Controlled Two-Arm Study Evaluating the Safety and Efficacy of the Iontophoretic Administration of Lidocaine and Epinephrine Using Lidocaine Iontophoretic Drug Delivery System (IDDS) to Provide Local Anesthesia for Venipuncture in Healthy Adult Volunteer Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dharma Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dharma Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness of administering Lidocaine and
      Epinephrine using an iontophoretic device treatment to provide local anesthesia to healthy
      adult volunteer subjects undergoing venipuncture.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Following the iontophoresis treatment an IV will be inserted into the treatment area and the amount of pain will be assessed using the median visual analog pain scale (VAS).</measure>
    <time_frame>4 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Monitor the nature and frequency of adverse events associated with the iontophoretic device through observation during treatment.</measure>
    <time_frame>4 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determining the duration of anesthesia through standard pin prick testing.</measure>
    <time_frame>4 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Local Anesthesia</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Contains Lidocaine and Epinephrine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Contains Epinephrine</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Iontophoretic Drug Delivery System with Lidocaine/Epinephrine</intervention_name>
    <description>Active- 10.5% Lidocaine/0.179% Epinephrine</description>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Iontophoretic Drug Delivery System with Epinephrine</intervention_name>
    <description>Placebo- 0.179% Epinephrine</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects may be of any race, either sex, and must be &gt;18 years of age

          -  Healthy subjects as per medical screening

          -  Subjects must have intact, healthy skin (no tattoos, surgical scars, skin infections,
             etc.) where the iontophoresis treatment will be performed

          -  Subjects must be alert, oriented, mentally competent, and able to understand and
             comply with the requirements of the study

          -  Subjects must have signed and dated a written informed consent

          -  Female subjects of childbearing potential must have a negative pregnancy test result
             prior to the iontophoresis treatment

        Exclusion Criteria:

          -  Subjects with a known allergy or sensitivity to lidocaine, epinephrine or other local
             anesthetics of the amide or ester type

          -  Subjects with a know sensitivity to any components (e.g. adhesives) of the
             IDDSSubjects who have undergone venipuncture in the treatment area within the prior 2
             weeks or longer if bruising or hematoma is apparent

          -  Subjects who have taken an analgesic pain medication during the 24-hour period prior
             to the venipuncture in the posterior surface of the hand

          -  Subjects with skin allergies or have skin diseases (e.g. psoriasis, eczema

          -  Subjects with an open skin lesion at the treatment site

          -  Subjects who are pregnant or breastfeeding

          -  Subjects exposed to an investigational drug or device within the past 30 days or are
             involved concurrently in other treatment clinical trials

          -  Subjects who participated in previous DTI/Transcu clinical studies related to this
             product

          -  Subjects with known concurrent illness

          -  Subjects with &quot;current&quot; known/admitted substance abuse (alcohol/drug)

          -  Subjects with pacemakers and/or externally mounted electronic devices

          -  Current or history of conditions that contraindicate use of iontophoretic treatment or
             venipuncture
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Advanced Clinical Research Institute</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vince &amp; Associates Clinical Research</name>
      <address>
        <city>Overland Park</city>
        <state>Missouri</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2009</study_first_submitted>
  <study_first_submitted_qc>April 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2009</study_first_posted>
  <last_update_submitted>June 22, 2009</last_update_submitted>
  <last_update_submitted_qc>June 22, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2009</last_update_posted>
  <responsible_party>
    <name_title>Ron Berenson, Acting Medical Director</name_title>
    <organization>Dharma Therapeutics Inc.</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>August 25, 2009</submitted>
    <returned>September 29, 2009</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

